Cited by 685Cystic Fibrosis Research AdvancesGenetic and Kidney Cyst DiseasesNeonatal Respiratory Health Research

The DOI matches its Crossref record; 194 of the 195 references it cites were found in a registry or an index.

Cystic fibrosis

Open access

Shteinberg, Michal, Haq, Iram J, Polineni, Deepika, Davies, Jane C·2021·The Lancet

Open this paper in CoChat — free account

Abstract

Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characterised by chronic pulmonary infection and inflammation, pancreatic exocrine insufficiency, male infertility, and might include several comorbidities such as cystic fibrosis-related diabetes or cystic fibrosis liver disease. This autosomal recessive disease is diagnosed in many regions following newborn screening, whereas in other regions, diagnosis is based on a group of recognised multiorgan clinical manifestations, raised sweat chloride concentrations, or CFTR mutations. Disease that is less easily diagnosed, and in some cases affecting only one organ, can be seen in the context of gene variants leading to residual protein function. Management strategies, including augmenting mucociliary clearance and aggressively treating infections, have gradually improved life expectancy for people with cystic fibrosis. However, restoration of CFTR function via new small molecule modulator drugs is transforming the disease for many patients. Clinical trial pipelines are actively exploring many other approaches, which will be increasingly needed as survival improves and as the population of adults with cystic fibrosis increases. Here, we present the current understanding of CFTR mutations, protein function, and disease pathophysiology, consider strengths and limitations of current management strategies, and look to the future of multidisciplinary care for those with cystic fibrosis.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32542-3

Cites

194 of 194 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Standardisation of spirometry
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Identification of the Cystic Fibrosis Gene: Genetic Analysis
Kerem, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., & Tsui, L.-C. (1989) · Science · doi:10.1126/science.2570460 · Cited by 4,142
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T., & Cheng, Z. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,520
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
Self-citation
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Self-citation
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Self-citation
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., PEPE, M. S., Quan, J. M., Otto, K., Montgomery, A. B., Williams‐Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,296
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match
Chambers, D. C., Cherikh, W. S., Harhay, M. O., Hayes, D., Hsich, E., Khush, K. K., Meiser, B., Potena, L., Rossano, J. W., Toll, A. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.001 · Cited by 1,269
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S. L., Davies, J. C., Burgel, P., Tullis, E., Castaños, C., Castellani, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 1,081
Self-citation

Show all 195 references

Research works printed but not linked: 2

Saunders, 2016, Developments in multibreath washout testing in children with cystic fibrosis, Curr Med Res Opin, 33, 1
2015, Symposium Summaries, Pediatr Pulmonol, 50, S108

Sorted by citations

Items 201–300 of 685

In Utero Gene Therapy and its Application in Genetic Hearing Loss
Kong, C., Yin, G., Wang, X., & Sun, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400193 · Cited by 10
Surface Hydration Protects Cystic Fibrosis Airways from Infection by Restoring Junctional Networks
Simonin, J., Lüscher, A., Losa, D., Badaoui, M., van Delden, C., Köhler, T., & Chanson, M. (2022) · Cells · doi:10.3390/cells11091587 · Cited by 10
Pancreatic involvement in celiac disease
Balaban, D. V., Enache, I., Ciochina, M., Popp, A., & Jinga, M. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i24.2680 · Cited by 10
Translation termination codons in protein synthesis and disease
Lombardi, S., Testa, M. F., Pinotti, M., & Branchini, A. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.06.001 · Cited by 10
Editorial: Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
Ribeiro, C. M. P., McElvaney, N. G., & Cabrini, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794854 · Cited by 10
Obstructive sleep apnea in children with cystic fibrosis on highly effective modulator therapy
Shakkottai, A., Kim, S., & Mitchell, R. B. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27061 · Cited by 9
Evidence for altered immune-structural cell crosstalk in cystic fibrosis revealed by single cell transcriptomics
Berg, M., Krabbendam, L., van der Ploeg, E. K., van Nimwegen, M., van der Veer, T., Banchero, M., Carpaij, O. A., Hoogenboezem, R. M., van den Berge, M., Bindels, E. M., et al. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.01.016 · Cited by 9
Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis
Truong, N. H., Benaboud, S., Bouazza, N., Barboura, M., Bardin, E., Miralles, M., Lui, G., Bournaud, L. F., Rouillon, S., Bihouée, T., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70245 · Cited by 9
Translational Research in Cystic Fibrosis: From Bench to Beside
Garcia, L. D. C. E., Petry, L. M., GERMANI, P. A. V. D. S., Xavier, L. F., de Barros, P. B., Meneses, A. D. S., Prestes, L. M., Bittencourt, L. B., Pieta, M. P., Friedrich, F., et al. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.881470 · Cited by 9
Progress and challenges in fungal lung disease in cystic fibrosis
Hong, G. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000921 · Cited by 10
Modeling of Respiratory Diseases Evolving with Fibrosis from Organoids Derived from Human Pluripotent Stem Cells
Chamorro-Herrero, I., & Zambrano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054413 · Cited by 9
SERS Microsensors for the Study of pH Regulation in Cystic Fibrosis Patient-Derived Airway Cultures
Skinner, W. H., Robinson, N., Hardisty, G. R., Gray, R. D., & Campbell, C. J. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00279 · Cited by 9
Beyond insulin: Unraveling the complex interplay of ER stress, oxidative damage, and CFTR modulation in CFRD
Umashankar, B., Eliasson, L., Ooi, C. Y., Kim, K. W., Shaw, J., & Waters, S. A. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.06.004 · Cited by 9
What diagnostic tests are available for respiratory infections or pulmonary exacerbations in cystic fibrosis: A scoping literature review
Naseem, R., Howe, N., Williams, C. J., Pretorius, S., & Green, K. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.07.005 · Cited by 9
Competitive fitness of Pseudomonas aeruginosa isolates in human and murine precision-cut lung slices
Cramer, N., Nawrot, M. L., Wege, L., Dorda, M., Sommer, C., Danov, O., Wronski, S., Braun, A. C., Jonigk, D. D., Fischer, S., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.992214 · Cited by 9
A Multicentre Italian Study on the Psychological Impact of an Inconclusive Cystic Fibrosis Diagnosis after Positive Neonatal Screening
Tosco, A., Marino, D., Polizzi, S., Tradati, V., Padoan, R., Giust, C., Fabrizzi, B., Taccetti, G., Merli, L., & Terlizzi, V. (2023) · Children · doi:10.3390/children10020177 · Cited by 9
Evolution of nutritional management in children with cystic fibrosis – a narrative review
Smith, C., Lowdon, J., Noordhoek, J., & Wilschanski, M. A. (2024) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.13298 · Cited by 8
Assessing the Potential of N-Butyl- l -deoxynojirimycin ( l -NBDNJ) in Models of Cystic Fibrosis as a Promising Antibacterial Agent
Esposito, A., Rossi, A., Stabile, M. R., Pinto, G., Fino, I. D., Melessike, M., Tamanini, A., Cabrini, G., Lippi, G., Aureli, M., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00044 · Cited by 8
Aspergillus in Children and Young People with Cystic Fibrosis: A Narrative Review
Chesshyre, E. L. D., Wooding, E. L., Sey, E. A., & Warris, A. (2025) · Journal of Fungi · doi:10.3390/jof11030210 · Cited by 8
Modeling reciprocal adaptation of Staphylococcus aureus and Pseudomonas aeruginosa co-isolates in artificial sputum medium
Wang, Z., Giedraitis, E., Knoop, C., Breiner, D. J., Phelan, V. V., & Françoise Van Bambeke, A. (2025) · Biofilm · doi:10.1016/j.bioflm.2025.100279 · Cited by 8
Polycationic nanoparticles for cascaded antibiosis and LPS- detoxifying via co-delivery of antibiotics and TLR siRNA in bacterial infected diseases treatment
Zhang, Y., Huangfu, Y., Xu, L., Zhao, Z., Su, Q., Li, H., Zhang, Y., Zhang, C., Huang, P., Dong, A., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.164349 · Cited by 8
Autophagy in the lung: guardian of homeostasis or driver of disease
Kim, H., Wang, W., Dobrescu, I., Lee, J., Martorelli, J., Wang, S. R., & Guo, J. Y. (2025) · Autophagy Reports · doi:10.1080/27694127.2025.2568537 · Cited by 8
Beyond the mutations: spatiotemporal regulation of CFTR by cAMP and calcium signaling in epithelial physiology and cystic fibrosis
Varga, A., Kiss, A. K., Crul, T., Madácsy, T., Pallagi, P., & Maléth, J. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00836-1 · Cited by 8
Short‐term effects of a novel bronchial drainage device: A pilot cohort study in subjects with cystic fibrosis
Schmidt, H., Toth, M., Kappler‐Schorn, C., Siebeneich, U., Bode, S. F. N., & Fabricius, D. (2022) · Health Science Reports · doi:10.1002/hsr2.812 · Cited by 8
Learning from cystic fibrosis: How can we start to personalise treatment of Children’s Interstitial Lung Disease (chILD)?
Bush, A. (2023) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2023.11.001 · Cited by 8
Genetic Variants Associated with Hypertension Risk: Progress and Implications
Curtis, D. (2024) · Pulse · doi:10.1159/000536505 · Cited by 8
Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor
Gruber, W., Stehling, F., Blosch, C., Dillenhoefer, S., Olivier, M., Brinkmann, F., Koerner‐Rettberg, C., Sutharsan, S., Mellies, U., Taube, C., et al. (2024) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2024.1284878 · Cited by 10
Cystic fibrosis-related chronic rhinosinusitis: the key role of a comprehensive evaluation in the era of highly effective modulator therapy
Minzoni, A., Mazzetti, L., Orlando, P., Licci, G., Taccetti, G., Bresci, S., & Maggiore, G. (2024) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-024-08888-3 · Cited by 8
Longitudinal Magnetic Resonance Imaging of Changes in Lung Morphology and Perfusion in Children with Cystic Fibrosis from Infancy Through Adolescence
Wielpütz, M. O., Stahl, M., Triphan, S. M. F., Wucherpfennig, L., Leutz-Schmidt, P., Gestewitz, S., Steinke, E., Graeber, S. Y., Kauczor, H., Eichinger, M., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202404-396oc · Cited by 8
Cystic fibrosis newborn screening: Five‐year experience from a tertiary care center
Büyükşahin, H. N., Emiralioğlu, N., Özsezen, B., Tural, D. A., Sunman, B., Güzelkaş, İ., Tezel, B., Erden, D. D., Yalçın, E., Doğru, D., et al. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25778 · Cited by 8
Evaluation of the Efficiency of Random and Diblock Methacrylate-Based Amphiphilic Cationic Polymers against Major Bacterial Pathogens Associated with Cystic Fibrosis
Casanova, M., Olleik, H., Hdiouech, S., Roblin, C., Cavalier, J., Point, V., Jeannot, K., Caron, B., Perrier, J., Charriau, S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12010120 · Cited by 8
Description of the clinical picture and assessment of functional activity of the CFTR channel in a patient with a complex allele [S466X; R1070Q]
Krasnova, M., Melyanovskaya, Y. L., Krasovskiy, S., Bulatenko, N., Efremova, A. S., Bukharova, T. B., & Goldshtein, D. V. (2023) · PULMONOLOGIYA · doi:10.18093/0869-0189-2023-33-2-233-242 · Cited by 8
Therapeutic potential of phytochemicals for cystic fibrosis
Baharara, H., Kesharwani, P., Johnston, T. P., & Sahebkar, A. (2023) · BioFactors · doi:10.1002/biof.1960 · Cited by 8
Outcome of patients with cystic fibrosis colonized byScedosporiumandLomentosporaspecies: A longitudinal cohort study
Parize, P., Fleury, M. J. J., Bourdy, S., Persat, F., Touzet, S., Bienvenu, A., Wallon, M., Reix, P., Bouchara, J., & Durieu, I. (2023) · Medical Mycology · doi:10.1093/mmy/myad051 · Cited by 8
Organoid-on-a-chip (OrgOC): Advancing cystic fibrosis research
Zheng, M., Erice, E., Wang, H., Zhang, L., & Lawrie, C. H. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102148 · Cited by 8
Adverse Events and Drug Interactions Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment: A Descriptive Study Across Australian, Canadian, and American Adverse Event Databases
Thiruchelvam, T., Lim, C. X., Munro, C., Chan, V. W. S., Jayasuria, G., Coulthard, K. P., Wark, P. A. B., & Suppiah, V. (2025) · Life · doi:10.3390/life15081256 · Cited by 7
The STING/TBK1/IRF3/IFN type I pathway is defective in cystic fibrosis
Occhigrossi, L., Rossin, F., Villella, V. R., Esposito, S., Abbate, C., D’Eletto, M., Farrace, M. G., Tosco, A., Nardacci, R., Fimia, G. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093212 · Cited by 7
Clinical and genetic features of cystic fibrosis in Japan
Kozawa, Y., Yamamoto, A., Nakakuki, M., Fujiki, K., Kondo, S., Okada, T., Fukuyasu, T., Yamaguchi, M., Taniguchi, I., Nomura, N., et al. (2023) · Journal of Human Genetics · doi:10.1038/s10038-023-01160-2 · Cited by 7
Cystic fibrosis: Epidemiology, clinical manifestations, diagnosis and treatment
Cáceres, L. D., & Zamarrón, E. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.06.013 · Cited by 7
STING-Associated Vasculopathy with Onset in Infancy: A Review Focusing on Pathophysiology and Treatment Options
Drougkas, K., Smerla, R., Skarlis, C., & Mavragani, C. P. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4040024 · Cited by 7
Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force
Hoppe, J. E., Sjoberg, J., Hong, G., Poch, K. R., Zemanick, E. T., Thee, S. A., Edmondson, C. L., Patel, D. R., Sathe, M., Borowitz, D., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.02.011 · Cited by 7
Akt-Driven TGF-β and DKK1 Secretion Impairs F508del Cystic Fibrosis Airway Epithelium Polarity
Idris, T., Bachmann, M., Bacchetta, M., Wehrle‐Haller, B., Chanson, M., & Badaoui, M. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0408oc · Cited by 7
The Role of the Microbiome in Pediatric Respiratory Diseases
Zemanick, E. T., & Rosas‐Salazar, C. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.02.026 · Cited by 7
Single‐cell RNA sequencing of cystic fibrosis liver disease explants reveals endothelial complement activation
Declercq, M., Treps, L., Geldhof, V., Conchinha, N. V., de Rooij, L. P. M. H., Subramanian, A., Feyeux, M., Cotinat, M., Boeckx, B., Vinckier, S., et al. (2024) · Liver International · doi:10.1111/liv.15963 · Cited by 7
A systematic review of the epidemiology of cystic fibrosis in arab countries: An update
Hammoudeh, S., Aqel, S., Mukthar, F., Chandra, P., & Janahi, I. A. (2024) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2024.101697 · Cited by 7
Enhanced CFTR modulator efficacy in ΔF508 CFTR mouse organoids by ablation of RFFL ubiquitin ligase
Hinata, D., Fukuda, R., Ishiguro, H., Kamada, Y., & Okiyoneda, T. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150433 · Cited by 7
Characterization of Exosomes Released from Mycobacterium abscessus‐Infected Macrophages
Vermeire, C. A., Tan, X., Ramos‐Leyva, A., Wood, A., Kotey, S. K., Hartson, S. D., Liang, Y., Liu, L., & Cheng, Y. (2024) · PROTEOMICS · doi:10.1002/pmic.202400181 · Cited by 7
The challenged urine bicarbonate excretion test in cystic fibrosis: A comprehensive analysis of urine acid/base parameters
Rousing, A. Q., Jeppesen, M., Jensen‐Fangel, S., Leipziger, J., Sørensen, M. V., & Berg, P. (2024) · Acta Physiologica · doi:10.1111/apha.14233 · Cited by 7
Pseudomonas aeruginosa PAO1 Is Attracted to Bovine Bile in a Novel, Cystic Fibrosis-Derived Bronchial Epithelial Cell Model
Behroozian, S., Sampedro, I., Dhodary, B., Her, S. C., Yu, Q., Stanton, B. A., & Hill, J. E. (2022) · Microorganisms · doi:10.3390/microorganisms10040716 · Cited by 7
Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
Terlizzi, V., Parisi, G. F., Ferrari, B., Castellani, C., Manti, S., Leonardi, S., & Taccetti, G. (2022) · Children · doi:10.3390/children9111625 · Cited by 7
Implementation of a comprehensive pharmacy‐driven immunization care process model in a pediatric cystic fibrosis clinic
Zobell, J. T., Moss, J., Creelman, J., Christensen, R., Jensen, B., Stewart, J., Ameel, K. N., & Asfour, F. (2023) · Pediatric Pulmonology · doi:10.1002/ppul.26306 · Cited by 7
Repeat or single-dose lentiviral vector administration to mouse lungs? It’s all about the timing
Donnelley, M., Cmielewski, P., Knight, E., Carpentieri, C., McCarron, A., Rout-Pitt, N., Parsons, D., & Farrow, N. (2023) · Gene Therapy · doi:10.1038/s41434-023-00403-3 · Cited by 7
It Takes Two to Tango! Protein–Protein Interactions behind cAMP-Mediated CFTR Regulation
Murabito, A., Bhatt, J., & Ghigo, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310538 · Cited by 7
Antibiotic potentiation and inhibition of cross-resistance in pathogens associated with cystic fibrosis
Kadeřábková, N., Furniss, R. C. D., Maslova, E., Potter, K. E., Eisaiankhongi, L., Bernal, P., Filloux, A., Landeta, C., González, D., McCarthy, R. R., et al. (2026) · eLife · doi:10.7554/elife.91082.3 · Cited by 7
Magnetic Resonance Imaging in the Clinical Evaluation of Lung Disorders: Current Status and Future Prospects
Wu, L., Gao, C., Wu, T., Kong, N., Zhang, Z., Li, J., Fan, L., & Xu, M. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29802 · Cited by 6
The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy
Fajac, I., Jain, R., Mall, M. A., Rubin, B. K., & Flume, P. A. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202408-800fr · Cited by 6
Oxylipin profile in saliva from patients with cystic fibrosis reveals a balance between pro-resolving and pro-inflammatory molecules
Carnovale, V., Castaldo, A., Minno, A. D., Gelzo, M., Iacotucci, P., Illiano, A., Pinto, G., Castaldo, G., & Amoresano, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-09618-7 · Cited by 6
Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
Granger, E., Davies, G., & Keogh, R. H. (2023) · Thorax · doi:10.1136/thorax-2023-220031 · Cited by 6
TNFRSF1B Signaling Blockade Protects Airway Epithelial Cells from Oxidative Stress
Checa, J., Fiol, P., de Guevara, M. L., & Aran, J. M. (2024) · Antioxidants · doi:10.3390/antiox13030368 · Cited by 6
Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis
Merlo, C. A., McGarry, L. J., Thorat, T., Nguyen, C., DerSarkissian, M., Muthukumar, A., Healy, J., Brookhart, M. A., & Rubin, J. L. (2024) · Thorax · doi:10.1136/thorax-2023-220559 · Cited by 6
Burkholderia cepacia in cystic fibrosis children and adolescents: overall survival and immune alterations
Шмарина, Г. В., Pukhalskaya, D. A., Shmarin, V., Semykin, S. Y., Avakyan, L. V., Krasovsky, S. A., Goryainova, A., Kostyuk, S. V., Zinchenko, R. A., & Kashirskaya, N. Y. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1374318 · Cited by 6
Nutrient conditions affect antimicrobial pharmacodynamics in Pseudomonas aeruginosa
Kok, M., Hankemeier, T., & van Hasselt, J. G. C. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01409-24 · Cited by 6
A Novel LC-MS/MS Method for the Measurement of Elexacaftor, Tezacaftor and Ivacaftor in Plasma, Dried Plasma Spot (DPS) and Whole Blood in Volumetric Absorptive Microsampling (VAMS) Devices
Pigliasco, F., Cafaro, A., Barco, S., Cresta, F., Casciaro, R., Pedemonte, N., Mattioli, F., Castellani, C., & Cangemi, G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020200 · Cited by 6
The role of islet CFTR in the development of cystic fibrosis-related diabetes: A semi-systematic review
Engström, M., Westholm, E., Wendt, A., & Eliasson, L. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.04.006 · Cited by 6
Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation
Henriksen, E. H., Sandvik, R. M., Olsen, M. F., Pressler, T., Bryrup, T., Leo‐Hansen, C., Nielsen, B. U., Højte, C., Skov, M., Buchvald, F. F., et al. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71166 · Cited by 6
Treatment With LAU-7b Complements CFTR Modulator Therapy by Improving Lung Physiology and Normalizing Lipid Imbalance Associated With CF Lung Disease
Centorame, A., Dumut, D. C., Youssef, M., Ondra, M., Kianicka, I., Shah, J., Paun, R. A., Oždian, T., Hanrahan, J. W., Gusev, E., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876842 · Cited by 6
Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies
Alicandro, G., Daccò, V., Cariani, L., Rosazza, C., Sciarrabba, C. S., Ferraro, F., Lanfranchi, C., Medino, P., Girelli, D., & Colombo, C. (2022) · Biomedicines · doi:10.3390/biomedicines10081998 · Cited by 7
Clinical Advances in Cystic Fibrosis
Imperlini, E., & Papa, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216306 · Cited by 6
Impact of COVID-19 on Lung Disease in People with Cystic Fibrosis: A 6-Month Follow-Up Study on Respiratory Outcomes
Medino, P., Alicandro, G., Rosazza, C., Ciciriello, F., Gramegna, A., Biffi, A., Daccò, V., Lucidi, V., Cipolli, M., Boraso, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112771 · Cited by 6
Alteration in glucocorticoids secretion and metabolism in patients affected by cystic fibrosis
Podgórski, R., Sumińska, M., Rachel, M., Fichna, M., Fichna, P., & Mazur, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1074209 · Cited by 6
Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
Alicandro, G., Orena, B. S., Rosazza, C., Cariani, L., Russo, M. C., Zatelli, M., Badolato, R., Gramegna, A., Blasi, F., & Daccò, V. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.041 · Cited by 6
Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis
Patel, N., Ansar, M., Pham, A., Thomsen, K. F., McKinzie, C. J., Polineni, D., Esther, C. R., & Brown, R. F. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26831 · Cited by 6
Self-citation
Human Amniotic Mesenchymal Stem Cells and Fibroblasts Accelerate Wound Repair of Cystic Fibrosis Epithelium
Beccia, E., Daniello, V., Laselva, O., Leccese, G., Mangiacotti, M., Gioia, S. D., Bella, G. L., Guerra, L., Matteo, M., Angiolillo, A., et al. (2022) · Life · doi:10.3390/life12050756 · Cited by 6
Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers
Gürsoy, T. R., Asfuroğlu, P., Eyüboğlu, T. Ş., Aslan, A. T., Yılmaz, A. İ., Ünal, G., Kibar, B. S., Pekcan, S., Hangül, M., Köse, M., et al. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04766-4 · Cited by 6
Inhalable mRNA therapeutics for pulmonary diseases: Challenges in delivery and advances in carrier design
Liang, Y., Tan, X., Yang, Y. R., Zhang, J., Gao, X., Yin, M., Gao, H., Yang, S. X., & Zhang, K. (2025) · Nano Research · doi:10.26599/nr.2025.94907874 · Cited by 6
Elexacaftor/tezacaftor/ivacaftor corrects salt-wasting in cystic fibrosis
Berg, P., Rousing, A. Q., Jensen‐Fangel, S., Bandulik, S., Warth, R., Sørensen, M. V., Jeppesen, M., & Leipziger, J. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.12.006 · Cited by 5
Pathophysiology of cystic fibrosis-related liver disease
Palmiotti, A., Bertolini, A., & Fiorotto, R. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001151 · Cited by 6
Survival-Adjusted FEV1 and BMI Percentiles for Patients with Cystic Fibrosis before the Era of Triple CFTR Modulator Therapy in Germany
Dittrich, S. A., Dumke, M., Kapl, F., Schneider, P., Wege, S., Gräber, S. Y., Stahl, M., Herth, F. J. F., Naehrlich, L., Mall, M. A., et al. (2023) · Respiration · doi:10.1159/000529524 · Cited by 5
The development of paranasal sinuses in patients with cystic fibrosis: sinuses volume analysis
Kałużna-Młynarczyk, A., Pucher, B., Jakub, S., Kotowski, M., Jończyk‐Potoczna, K., & Szydlowski, J. (2023) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-023-08236-x · Cited by 5
CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways
Wu, M., & Chen, J.-H. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1385661 · Cited by 5
Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?
Okiyoneda, T., Borgo, C., Bosello-Travain, V., Pedemonte, N., & Salvi, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05295-z · Cited by 5
Advances in applications of the CRISPR/Cas9 system for respiratory diseases
Ajaykumar, C., Rajkumar, S., Suresh, B., Birappa, G., Gowda, D. A. A., Jayachandran, A., Kim, K.-S., Hong, S.-H., & Ramakrishna, S. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.014 · Cited by 5
Therapeutic Interventions for Pseudomonas Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials
Alqasmi, M. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216530 · Cited by 5
The Feasibility and Validity of Home Spirometry for People with Cystic Fibrosis: Is It Comparable to Spirometry in the Clinic?
Sopiadou, A., Gioulvanidou, M., Kogias, C., Chrysochoou, E.-A., Kalaitzopoulou, I., & Hatziagorou, E. (2025) · Children · doi:10.3390/children12030277 · Cited by 5
Leptin Levels and Bone Mineral Density: A Friend or a Foe for Bone Loss? A Systematic Review of the Association Between Leptin Levels and Low Bone Mineral Density
Cosme, D., & Gomes, A. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052066 · Cited by 5
Cystic fibrosis–related kidney disease—emerging morbidity and disease modifier
Hart, M., Kumar, M., Goswami, H. B., Harris, W. T., Skopelja‐Gardner, S., & Swiatecka‐Urban, A. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-06715-3 · Cited by 5
Comparative Efficacy of CFTR Modulators: A Network Meta-analysis
IFTIKHAR, I. H., Rao, S. T., Nadama, R., Janahi, I. A., & BaHammam, A. S. (2025) · Lung · doi:10.1007/s00408-025-00802-w · Cited by 5
Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce Pseudomonas aeruginosa burden in mice
Hale, M. R., Takehara, K. K., Thouvenel, C. D., Moustafa, D. A., Repele, A., Fontana, M. F., Netland, J., McNamara, S., Gibson, R. L., Goldberg, J. B., et al. (2025) · eLife · doi:10.7554/elife.98851.3 · Cited by 5
Molecular Advances in Cholestatic Liver Diseases
Memon, R. A., & Saxena, R. (2025) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000502 · Cited by 5
Mental health care needs in cystic fibrosis: A scoping review
Tickner, C., Holland, L., Wark, P. A. B., Hilton, J., Morrison, C., KAY‐LAMBKIN, F. J., & Heinsch, M. (2022) · Social Work in Health Care · doi:10.1080/00981389.2022.2060422 · Cited by 5
Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis
Ferrari, V., Terlizzi, V., & Stagi, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144041 · Cited by 5
Intra Uterine Insemination in Two Couples with HPV Detection by Hyaluronidase-Based Swim-up Washing: Cases Report
Cosci, I., Toni, L. D., Prosperi, F. V. D., Bedoni, C., Ramirez, R., Buonfantino, G., Ferlin, A., & Garolla, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm13010006 · Cited by 5
Inherited causes of exocrine pancreatic insufficiency in pediatric patients: clinical presentation and laboratory testing
Yuzyuk, T. N., Nelson, H. A., & Johnson, L. M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2179968 · Cited by 5
Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial
Ayats, R., García, M. B., Cordobilla, B., la Cruz, O. A.-D., González, M. G., Castro‐Marrero, J., López-Rico, I., & Domingo, J. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113704 · Cited by 5
Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis
Fainardi, V., Skenderaj, K., Ciuni, A., Milanese, G., Deolmi, M., Longo, F., Spaggiari, C., Sverzellati, N., Esposito, S., & Pisi, G. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107328 · Cited by 5
Bronchiectasis: from orphan disease to precision medicine
Choi, H., & Chalmers, J. D. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018122 · Cited by 5
Reversing the ion transport selectivity through arm modification of an artificial molecular hourglass
Huang, W., Wang, X., Ao, Y., Wang, Q., & Wang, D. (2023) · Chemical Communications · doi:10.1039/d3cc04573k · Cited by 5
Cyclic diacyl thioureas enhance activity of corrector Lumacaftor on F508del‐CFTR
Spallarossa, A., Pedemonte, N., Pesce, E., Millo, E., Cichero, E., Rosano, C., Lusardi, M., Iervasi, E., & Ponassi, M. (2023) · ChemMedChem · doi:10.1002/cmdc.202300391 · Cited by 5
Localization and function of humanized F508del-CFTR in mouse intestine following activation of serum glucocorticoid kinase 1 and Trikafta
Dastoor, P. K., Muiler, C., Garrison, A., Egan, M. E., dos Reis, D. C., Santos, A. K., & Ameen, N. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176771 · Cited by 5
TMEM16 proteins: Ca2+‑activated chloride channels and phospholipid scramblases as potential drug targets (Review)
Huang, Z., Iqbal, Z., Zhao, Z., Chen, X., Mahmmod, A., Liu, J., Li, W., & Deng, Z. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5405 · Cited by 5

Authors: Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C.
Affiliations: Technion – Israel Institute of Technology (IL)
Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
University of Kansas Medical Center (US)
Guy's and St Thomas' NHS Foundation Trust (GB)
ORCID: Shteinberg, Michal
Haq, Iram J
Polineni, Deepika
Davies, Jane C
Venue: The Lancet
Publisher: Elsevier BV
Published: 2021-06
Volume: 397
Issue: 10290
Pages: 2195-2211
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(20)32542-3
OpenAlex: W4205612199
Cited by: 682
References: 195
Citations by year: 2026: 96 · 2025: 132 · 2024: 147 · 2023: 160 · 2022: 131 · 2021: 14
FWCI: 18.21
Type: journal article
Language: en
Open access: green
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Institute for Health and Care Research (NIHR201402, CL-2018-01-002)
Cystic Fibrosis Trust (SRC 014)
Academy of Medical Sciences (SGL024\1027)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Neonatal Respiratory Health Research
Keywords: cystic fibrosis, CFTR mutations, CFTR function, mucus hydration, chronic lung infection, exocrine pancreatic insufficiency, male infertility, cystic fibrosis-related diabetes, cystic fibrosis liver disease, newborn screening, sweat test, CFTR modulator therapy, mucociliary clearance, disease pathophysiology, multidisciplinary care
MeSH terms: Bicarbonates, Chlorides, Cystic Fibrosis, Humans, Life Expectancy, Mucociliary Clearance, Mutation, Exocrine Pancreatic Insufficiency, Genetic Therapy, Cystic Fibrosis Transmembrane Conductance Regulator, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cystic fibrosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks